Her extensive development experience in immunology, inflammation, and neurology will further strengthen our team as we advance VENT-03, our first-in-class cGAS inhibitor, and VENT-02, our best-in ...

Ventus Therapeutics, a clinical-stage biopharmaceutical company with two novel small-molecule programs entering Phase 2 ...

This investigation centred on the combination of ATR inhibitors (VE822/AZD6738) with radiotherapy in vitro as a means of activating the cGAS/STING pathway the elicit an IFN-based inflammatory response ...

Chronic or heightened activation of cGAS-STING signaling has been associated with autoimmune diseases such as Aicardi-Goutières syndrome and other pathologies. Additionally, it is also a prominent ...

Her extensive development experience in immunology, inflammation, and neurology will further strengthen our team as we advance VENT-03, our first-in-class cGAS inhibitor, and VENT-02, our ...

Complementary experiments showed that, under in vitro experimental conditions, targeting these pathways via the antioxidant drug NAC, TLR9 antagonist and to a lesser extent cGAS-inhibitor, suppressed ...